Study on the Pharmacokinetics of Bromine Hexane Hydrochloride Tablets in Healthy Adults

Pharmacokinetics Clinical Trial

Official title:

Study on the Pharmacokinetics of Bromine Hexane Hydrochloride Tablets in Healthy Adults

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04672707
• Other study ID #: BCYY-BEFA-2020BCCT002
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: December 12, 2021
• Est. completion date: December 12, 2024

Study information

• Verified date: December 2020
• Source: Second Affiliated Hospital of Wenzhou Medical University
• Contact: Ting Li, PHD
• Phone: 0577-88002664
• Email: liting1021[@]aliyun.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical study is about increasing the dosage of bromine hexane hydrochloride to safety volume and continue to give it frequently in the new crown virus treatment could improve the efficacy.

Description:

The purpose is to study the pharmacokinetic characteristics and safety of bromine hexane hydrochloride in healthy adults after oral administration of bromine hexane hydrochloride tablets. Then to explore the mechanism related to the role of transmembrane serine proteases (TMPRSSs) through the study, and to provide the basis for the clinical rational administration of bromine hexane hydrochloride tablets.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 32
• Est. completion date: December 12, 2024
• Est. primary completion date: December 12, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Healthy adult males and non-pregnant non-lactating females aged 18-55 years, including boundary values, trial period Over 55 years of age);

2. Male body weight =50 kg, female body weight =45 kg, body mass index (BMI )19,282 Between, including boundary values;

3. Health, no heart, liver, kidney, digestive tract, nervous system, mental disorders and metabolic disease history;

4. Sign informed consent before the trial, fully understand the content, process and possible adverse reactions, and communicate well with the researchers.

Exclusion Criteria:

1. Have participated in any clinical trial within 90 days before the trial or plan to participate in other clinical trials during the trial;

2. Have undergone major surgery within 90 days before the trial or plan to undergo surgery within 3 months after the trial;

3. Blood loss or donation of more than 300 blood mL (excluding female physiological blood loss) within 90 days prior to the trial, or blood transfusion;

4. Suffering from esophageal reflux, gastric bleeding or peptic ulcer disease within 180 days prior to the trial, more than once a week with heartburn, or any surgical procedure that may affect drug absorption (e.g. cholecystectomy);

5. a person with a specific history of allergies (asthma, urticaria, eczema, etc.), or an allergic constitution (e.g. allergic to two or more drugs, food or pollen), or a known component of the drug*or analogues/lactose allergy/intolerance; *The main components of the test drug: bromine hexane hydrochloride, excipients: starch, lactose, magnesium stearate.

6. Use of any medication within 28 days prior to the trial, including the use of prescription, over-the-counter and/or alternative medicines (e.g., medicinal meals, herbal medicines, hemostatic or health products) and the use of hormonal contraception or vaccines;

7. History of substance abuse;

8. Urine screening for substance abuse (tetrahydrocannabinol, benzodiazepine, barbiturates, morphine, cocaine, methamphetamine) was positive;

9. More than 3 cigarettes per day during the 90 days before the test; Alcoholism, Over 7 drinks per week for women and over 14 drinks per week for men (1=150 mL wine =360 mL beer and 45 spirits);

10. Positive breath test;

11. The body temperature (ear temperature)=37.5?, the respiration was obviously abnormal, and the researchers thought it was not suitable to take part in the experiment. The systolic blood pressure >140 mmHg or <90 mmHg, diastolic blood pressure (diastolic blood pressure) was 90 mmHg or 60 times 100/min or >;

12. Positive human immunodeficiency virus antibody (HIV-Ab), hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab) or Treponema pallidum specific antibody (TPHA);

13. There are special requirements for diet, during the test can not comply with a unified diet;

14. Subjects refused to comply with the 48-hour ban on caffeine, alcohol, grapefruit and food (including tea, chocolate, coffee, cola, etc.);

15. Participants with partners refused to use effective contraception within 180 days from screening to completion of the trial;

16. Female subjects were positive for blood/urine pregnancy;

17. (c) Persons with renal insufficiency, impairment or previous urinary system disease;

18. hereditary galactose intolerance, lactase deficiency, or glucose-galactose malabsorption;

19. Halo acupuncture, halo blood and venous blood collection difficulties;

20. The physical examination has an obvious abnormality, and the researcher thinks it is not suitable to participate in the experiment;

21. Electrocardiogram examination has an obvious abnormality, and the researcher thinks it is not suitable to participate in the experiment;

22. Blood biochemistry, blood routine, urine routine examination have obvious abnormal, and the researchers think it is not suitable to participate in the test;

23. The subjects may not be able to complete the study for other reasons or may not be suitable for participation in the study.

Related Conditions & MeSH terms

• Pharmacokinetics

Intervention

Drug:
• Bromhexine Hydrochloride Tablet
32 mg
• Bromhexine Hydrochloride Tablet
48 mg
• Bromhexine Hydrochloride Tablet
64 mg
• Bromhexine Hydrochloride Tablet
80mg

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Second Affiliated Hospital of Wenzhou Medical University	Wanbangde Pharmaceutical Group Co., LTD

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax	Maximum observed concentration	up to 48 hours
Secondary	Area under curve (AUC 0-16h)	16 hour dosing period; 3 dosing periods each separated by 2 day washout	up to 48 hours
Secondary	AUC(AUC to infinity)	16 hour dosing period; 3 dosing periods each separated by 2 day washout	up to 48 hours
Secondary	AUC_%Extrap	The proportion of the AUC (AUC to infinity) from the last point until we theoretically extrapolate to infinity	up to 48 hours
Secondary	Time of maximum concentration (Tmax)	16 hour dosing period; 3 dosing periods each separated by 2 day washout	2 to 2.5 hours
Secondary	Clearance rate(CL)	Apparent clearance rate	up to 48 hours
Secondary	Vd	Apparent volume of distribution	up to 48 hours
Secondary	t1/2	16 hour dosing period; 3 dosing periods each separated by 2 day washout	5 hour
Secondary	?z	Terminal disposition rate constant	up to 48 hours